Paper36914633
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.
Weisser NE and 38 others. Nat Commun, 2023. Cited by 167 papers, by iCite.
Cite this record
ConductScience Library. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Papers, record 36914633. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36914633
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Antibodies, Bispecific | Major topic |
| Breast Neoplasms | Major topic |
| Humans | |
| Female | |
| Xenograft Model Antitumor Assays | |
| Cell Line, Tumor | |
| Trastuzumab | |
| Erb-b2 Receptor Tyrosine Kinases | |
| Antibody-Dependent Cell Cytotoxicity |
Source PubMed
References73
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20068220 | A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. | Blood | 2010 | https://conductscience.org/library/papers/20068220 | PubMed |
| 2 | 26249021 | Single molecule localization deep within thick cells; a novel super-resolution microscope. | J Biophotonics | 2016 | https://conductscience.org/library/papers/26249021 | PubMed |
| 3 | 27255951 | Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk. | Nat Commun | 2016 | https://conductscience.org/library/papers/27255951 | PubMed |
| 4 | 11521719 | The basic biology of HER2. | Ann Oncol | 2001 | https://conductscience.org/library/papers/11521719 | PubMed |
| 5 | 22471661 | Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. | Crit Rev Oncog | 2012 | https://conductscience.org/library/papers/22471661 | PubMed |
| 6 | 8102322 | Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8102322 | PubMed |
| 7 | 12393572 | In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. | Blood | 2003 | https://conductscience.org/library/papers/12393572 | PubMed |
| 8 | 24492309 | HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. | MAbs | 2014 | https://conductscience.org/library/papers/24492309 | PubMed |
| 9 | 20728210 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. | Lancet | 2010 | https://conductscience.org/library/papers/20728210 | PubMed |
| 10 | 22426455 | Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. | Arch Biochem Biophys | 2012 | https://conductscience.org/library/papers/22426455 | PubMed |
| 11 | 12543813 | Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. | Cancer Res | 2003 | https://conductscience.org/library/papers/12543813 | PubMed |
| 12 | 21559149 | Simultaneous multiple-emitter fitting for single molecule super-resolution imaging. | Biomed Opt Express | 2011 | https://conductscience.org/library/papers/21559149 | PubMed |
| 13 | 10941909 | Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors. | Cancer Immunol Immunother | 2000 | https://conductscience.org/library/papers/10941909 | PubMed |
| 14 | 28639341 | Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions. | Protein Sci | 2017 | https://conductscience.org/library/papers/28639341 | PubMed |
| 15 | 10742152 | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. | Nat Med | 2000 | https://conductscience.org/library/papers/10742152 | PubMed |
| 16 | 10692345 | Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. | Biophys J | 2000 | https://conductscience.org/library/papers/10692345 | PubMed |
| 17 | 27828362 | Real-time 3D stabilization of a super-resolution microscope using an electrically tunable lens. | Opt Express | 2016 | https://conductscience.org/library/papers/27828362 | PubMed |
| 18 | 15490369 | Molecular approach to breast cancer treatment. | Semin Oncol | 2004 | https://conductscience.org/library/papers/15490369 | PubMed |
| 19 | 20588256 | Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. | Mol Ther | 2010 | https://conductscience.org/library/papers/20588256 | PubMed |
| 20 | 15264254 | UCSF Chimera--a visualization system for exploratory research and analysis. | J Comput Chem | 2004 | https://conductscience.org/library/papers/15264254 | PubMed |
Cited by123
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958443 | HER2 in solid tumors: microenvironment features and multifaceted advances from mechanisms to clinical translation. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/42958443 | PubMed |
| 42930033 | Complement in HER2-Positive Breast Cancer: A Conditionally Protective Mechanism Under Attack. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/42930033 | PubMed |
| 42881857 | Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib. | J Clin Med | 2026 | https://conductscience.org/library/papers/42881857 | PubMed |
| 42878958 | A Meta-Analysis on Outcomes of Zanidatamab Plus Chemotherapy in Patients with Advanced HER2-positive Gastroesophageal Adenocarcinoma. | J Gastrointest Cancer | 2026 | https://conductscience.org/library/papers/42878958 | PubMed |
| 42860555 | Lactylation-Mediated HER2 Stabilization Promotes Trastuzumab Resistance in Gastric Cancer. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42860555 | PubMed |
| 42851488 | Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42851488 | PubMed |
| 42850399 | Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum. | Nat Rev Clin Oncol | 2026 | https://conductscience.org/library/papers/42850399 | PubMed |
| 42845595 | A shark variable new antigen receptor recognizes an occluded epitope of fibroblast activation protein. | bioRxiv | 2026 | https://conductscience.org/library/papers/42845595 | PubMed |
| 42835167 | Case Report: zanidatamab-based regimen as a potential later-line therapeutic option in HER2-amplified metastatic colorectal cancer. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42835167 | PubMed |
| 42780747 | Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives. | Front Oncol | 2026 | https://conductscience.org/library/papers/42780747 | PubMed |
| 42776793 | Advances in Bispecific Antibodies and Antibody-Drug Conjugates for Colorectal Cancer Treatment. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/42776793 | PubMed |
| 42773107 | Zanidatamab in patients with early stage HER2-positive breast cancer: the NeoZanHER phase 2 single-arm open-label trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/42773107 | PubMed |
| 42703442 | Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting. | J Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/42703442 | PubMed |
| 42688229 | Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen. | Front Immunol | 2026 | https://conductscience.org/library/papers/42688229 | PubMed |
| 42653742 | Functional Characteristics Derived from the Structural Design of Bispecific Antibodies. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653742 | PubMed |
| 42582644 | Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review. | Transl Breast Cancer Res | 2026 | https://conductscience.org/library/papers/42582644 | PubMed |
| 42559290 | Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42559290 | PubMed |
| 42547622 | The next generation of antibody-drug conjugates. | Nat Med | 2026 | https://conductscience.org/library/papers/42547622 | PubMed |
| 42493602 | Advancing antibody drug conjugates in gastrointestinal cancers. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42493602 | PubMed |
| 42463920 | Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination. | Acta Pharmacol Sin | 2026 | https://conductscience.org/library/papers/42463920 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36914633
GET https://conductscience.org/api/papers/v1/36914633/authors?page=2